CS802086A2 - Method of substituted imidazopyrrole,-pyridine and-azepine derivatives production - Google Patents
Method of substituted imidazopyrrole,-pyridine and-azepine derivatives productionInfo
- Publication number
- CS802086A2 CS802086A2 CS868020A CS802086A CS802086A2 CS 802086 A2 CS802086 A2 CS 802086A2 CS 868020 A CS868020 A CS 868020A CS 802086 A CS802086 A CS 802086A CS 802086 A2 CS802086 A2 CS 802086A2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- opt
- alkyl
- substd
- alkoxy
- etherified
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- MHOZZUICEDXVGD-UHFFFAOYSA-N pyrrolo[2,3-d]imidazole Chemical class C1=NC2=CC=NC2=N1 MHOZZUICEDXVGD-UHFFFAOYSA-N 0.000 title 1
- -1 alkanoyl alkanoyloxy Chemical group 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000001589 carboacyl group Chemical group 0.000 abstract 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 5
- 125000004423 acyloxy group Chemical group 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000004414 alkyl thio group Chemical group 0.000 abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 2
- 229910006069 SO3H Inorganic materials 0.000 abstract 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 2
- 125000004660 phenylalkylthio group Chemical group 0.000 abstract 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 2
- 102000014654 Aromatase Human genes 0.000 abstract 1
- 108010078554 Aromatase Proteins 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 125000005042 acyloxymethyl group Chemical group 0.000 abstract 1
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 abstract 1
- 125000004970 halomethyl group Chemical group 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
(A) Bicyclic imidazole derivs. of formula (Ia)-(Ic) and their salts are new. R1=H; alkyl opt. substd. by alkanoyl, NH2, mono- or dialkylamino, SO3H, COOH, alkoxycarbonyl, CONH2 or CN; 2-7C alkyl substd. by OH, alkoxy, halogen or alkanoyloxy; NO2, alkoxy, alkanoyl alkanoyloxy, phenylsulphonyloxy, alkylsulphonyloxy, alkylthio, alkylsulphinyl, alkylsulphonyl, alkanoylthio, NH2, mono- or dialkylamino, alkylenamino, morpholino, thiomorpholino, 1-piperazinyl, 4-alkyl-1-piperazinyl, trialkylammonio, SO3H, alkoxy sulphonyl, SO2NH2, mono- or dialkylsulphamoyl; iminomethyl opt. N-substd. by OH, alkoxy, alkanoyloxy, alkyl, phenyl or NH2; 2-7C alkanoyl or benzoyl; R2=H, alkyl, phenylalkyl, carboxyalkyl, alkoxycarbonylalkyl, halogen, OH, alkoxy, alkanoyloxy, SH, alkylthio, phenylalkylthio, phenylthio, alkanoylthio, COOH, alkoxycarbonyl or alkanoyl; R'1=R1, CH2OH, alkoxymethyl, halomethyl, alkanoyloxymethyl, halogen, OH, SH, CHO, COOH, alkoxycarbonyl, CONH2, mono- or dialkylcarbamoyl, CN, 5-tetrazolyl, 4,5-dihydro-2-oxazolyl (opt. substd. by alkyl) or CONHOH, n=0-4; R''1 =R1 or may be R'1 when n=0, 1, 3 or 4 or when n=2 and R2=phenyl alkyl, carboxyalkyl, alkoxycarbonylalkyl, alkanoyloxy, SH, alkylthio, phenylalkylthio, phenylthio, alkanoylthio, COOH, alkoxycarbonyl or alkanoyl; all alkyl, alkoxy and alkanoyl gps. are 'lower' unless otherwise stated; all phenyl gps. are opt. substd. by alkyl, alkoxy or halogen. - (B) The use of cpds. (Ia, R1=R, R2=R') (Ib: R'1=R, R2=R') and (Ic; R''1=R1, R2=R') for prepn. of medicaments for treating diseases responding to aromatase inhibition is claimed, where: R= H, opt. substd. alkyl, NO2, halogen, opt. etherified or esterified OH, opt. etherified, oxidised-etherified or esterified SH, NH2, mono- or disubstd. amino, ammonio, opt. functionally modified SO3H, COOH or CHO or 2-20C acyl; R'=H, opt. substd. alkyl, halogen, opt. etherified or esterified OH, opt. etherified, oxidised-etherified or esterified SH, opt. functionally modi
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS868020A CS268686B2 (en) | 1985-06-18 | 1986-11-05 | Method of substituted imidazopyrrole,-pyridine and-azepine derivatives production |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS854449A CS268672B2 (en) | 1984-06-20 | 1985-06-18 | Method of substituted imidazo-(1,5-a)pyridine derivatives production |
| CS868020A CS268686B2 (en) | 1985-06-18 | 1986-11-05 | Method of substituted imidazopyrrole,-pyridine and-azepine derivatives production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS802086A2 true CS802086A2 (en) | 1989-07-12 |
| CS268686B2 CS268686B2 (en) | 1990-04-11 |
Family
ID=5387250
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS868020A CS268686B2 (en) | 1985-06-18 | 1986-11-05 | Method of substituted imidazopyrrole,-pyridine and-azepine derivatives production |
| CS868022A CS268688B2 (en) | 1985-06-18 | 1986-11-05 | Method of substituted imidazopyrrole,-pyridine and-azepine derivatives production |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS868022A CS268688B2 (en) | 1985-06-18 | 1986-11-05 | Method of substituted imidazopyrrole,-pyridine and-azepine derivatives production |
Country Status (1)
| Country | Link |
|---|---|
| CS (2) | CS268686B2 (en) |
-
1986
- 1986-11-05 CS CS868020A patent/CS268686B2/en not_active IP Right Cessation
- 1986-11-05 CS CS868022A patent/CS268688B2/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CS268688B2 (en) | 1990-04-11 |
| CS268686B2 (en) | 1990-04-11 |
| CS802286A2 (en) | 1989-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK6392A (en) | Podophyllotoxin derivatives | |
| DE69229729D1 (en) | Wound healing | |
| DE3650499D1 (en) | Use of "cartilage-inducing factor" (CIF) for the treatment of hemato- or lymphopoietic diseases | |
| TR200201052T2 (en) | New class of cell differentiating agents and histone deacetylase inhibitors, and methods of use herein | |
| Cassin et al. | The effects of bumetanide and furosemide on lung liquid secretion in fetal sheep | |
| Schneider et al. | Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. | |
| IS3378A7 (en) | 1,4 - Dihydropyridines, and their method of manufacture as well as its therapeutic use | |
| CS802086A2 (en) | Method of substituted imidazopyrrole,-pyridine and-azepine derivatives production | |
| CS801886A2 (en) | Method of substituted imidazopyrrole,-pyridine and-azepine derivatives production | |
| NO880731L (en) | PROCEDURE FOR THE PREPARATION OF PHARMASOEYTIC ACTIVE Naphthalene Derivatives. | |
| DE60017147D1 (en) | USE OF GABAB RECEPTOR AGONISTS AND THEIR PHARMACEUTICALLY ACCEPTABLE DERIVATIVES IN THERAPY FOR THE CONSERVATION OF NICOTINE ABSTINENCE IN NICOTINE-DEPENDENT PATIENTS | |
| EA200100214A1 (en) | APPLICATION OF DERIVATIVES OF CAMPTOTECINE WITH REDUCED GASTROINTESTINAL TOXICITY | |
| ES405215A1 (en) | PROCEDURE FOR THE PREPARATION OF NEW TENO (3,2-D) PYRIMIDINES. | |
| NO950360D0 (en) | New Drug Containing 3-Phenylsulfonyl-3,7-diazabicyclo [3.3.1 Nonanone Compounds | |
| DK0533210T3 (en) | Protein C-containing pharmaceutical preparations as agents for inflammation. | |
| Tomono et al. | Synergistic potentiating effects of choline phosphate and ethanolamine on insulin-induced DNA synthesis in NIH 3T3 fibroblasts | |
| AU3818989A (en) | The use of substituted 3,4-dihydro-2h-benzopyrans as remedies for constructive functional disorders of the lungs and/or disorders of the efferent urinary passages | |
| Klos et al. | Prilocaine-induced methemoglobinemia in a child with Shwachman syndrome | |
| DE3889497D1 (en) | 3,4-dihydro-2-alkyl-3-oxo-N-aryl-2H- [1] benzothieno [3,2-e] -1,2-thiazine-4-carboxamide-1,1-dioxide. | |
| FR2307536A1 (en) | 5-Sulphomoyl-anthranilic acid derivs - 4-substd. by piperazino, with hypotensive activity | |
| Pecoits-Filho et al. | Roxadustat Treatment Results in Consistent Improvements in Hemoglobin (Hb) vs. Placebo: An Analysis of Three Multinational Randomized Clinical Trials in Patients with Non-Dialysis-Dependent CKD (NDD-CKD): TH-OR05 | |
| ES8604550A1 (en) | 5,6-Dihydro-4H-cyclopenta(b)thiophene-6-carboxylic acids, processes for their preparation and therapeutical agents containing them. | |
| EP0209089A3 (en) | Use of quinazolines in the preparation of a medicament for treating and preventing ischemic cardiac disease or arrhythmia | |
| FR2148363A1 (en) | Dihydrobenzopyran derivs - as cardiac and respiratory analeptic agents and hypo tensive agents | |
| Pergola et al. | Hemoglobin (Hb) Correction with Roxadustat Is Associated with Improved Iron Homeostasis in Patients with Dialysis-Dependent CKD (DD-CKD): TH-OR06 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Patent expired |
Effective date: 20000618 |